Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Senolytic Targeting of Bcl-2 Anti-Apoptotic Family Increases Cell Death in Irradiated Sarcoma Cells
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 3, Pages 386
Publisher
MDPI AG
Online
2021-01-22
DOI
10.3390/cancers13030386
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor positive breast cancer
- (2020) James R Whittle et al. CLINICAL CANCER RESEARCH
- CRISPR screens in cancer spheroids identify 3D growth-specific vulnerabilities
- (2020) Kyuho Han et al. NATURE
- The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation
- (2020) Nipa H. Patel et al. RADIATION RESEARCH
- Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma
- (2020) Jules Lansu et al. JAMA Oncology
- Surgery in reference centers improves survival of sarcoma patients: a nationwide study
- (2019) J -Y Blay et al. ANNALS OF ONCOLOGY
- BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
- (2019) Erinna F. Lee et al. Cell Death & Disease
- Neoadjuvant Radiotherapy to Facilitate Immediate Breast Reconstruction: A Systematic Review and Current Clinical Trials
- (2019) Puneet Singh et al. ANNALS OF SURGICAL ONCOLOGY
- Regulation of Survival Networks in Senescent Cells: From Mechanisms to Interventions
- (2019) Abel Soto-Gamez et al. JOURNAL OF MOLECULAR BIOLOGY
- Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
- (2019) Hubert Fleury et al. Nature Communications
- Neoadjuvant radiotherapy for rectal cancer management
- (2019) Gerard Feeney et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Hallmarks of Cellular Senescence
- (2018) Alejandra Hernandez-Segura et al. TRENDS IN CELL BIOLOGY
- Age and Age-Related Diseases: Role of Inflammation Triggers and Cytokines
- (2018) Irene Maeve Rea et al. Frontiers in Immunology
- AMG 176, a Selective MCL1 Inhibitor, is Effective in Hematological Cancer Models Alone and in Combination with Established Therapies
- (2018) Sean Caenepeel et al. Cancer Discovery
- Long-term effects of neoadjuvant radiotherapy, adjuvant radiotherapy, and chemotherapy-only on survival of locally advanced non-small cell lung Cancer undergoing surgery: a propensity-matched analysis
- (2018) Xinyu Wang et al. BMC CANCER
- The dynamic nature of senescence in cancer
- (2018) Soyoung Lee et al. NATURE CELL BIOLOGY
- Advances in Molecular Mechanisms and Treatment of Radiation-Induced Pulmonary Fibrosis
- (2018) Zhongjie Chen et al. Translational Oncology
- Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
- (2018) Adriana E. Tron et al. Nature Communications
- Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice
- (2017) Jin Pan et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Senescence-associated reprogramming promotes cancer stemness
- (2017) Maja Milanovic et al. NATURE
- From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
- (2017) Avi Ashkenazi et al. NATURE REVIEWS DRUG DISCOVERY
- In-depth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil
- (2017) Angélique Virgone-Carlotta et al. PLoS One
- Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis
- (2017) David Lagares et al. Science Translational Medicine
- Cellular senescence mediates fibrotic pulmonary disease
- (2017) Marissa J. Schafer et al. Nature Communications
- Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
- (2017) Akane Inoue-Yamauchi et al. Nature Communications
- High-Throughput Functional Genetic and Compound Screens Identify Targets for Senescence Induction in Cancer
- (2017) Liqin Wang et al. Cell Reports
- Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
- (2016) Yi Zhu et al. AGING CELL
- Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
- (2016) Ahmed Hamed Salem et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
- (2016) András Kotschy et al. NATURE
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in Radiation Therapy for Primary and Metastatic Adult Soft Tissue Sarcomas
- (2016) Philip Blumenfeld et al. Current Oncology Reports
- Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis
- (2016) Megan K. Ruhland et al. Nature Communications
- Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
- (2016) Reut Yosef et al. Nature Communications
- The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
- (2015) Yi Zhu et al. AGING CELL
- ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
- (2015) Shundong Cang et al. Journal of Hematology & Oncology
- Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
- (2015) B. A. Teicher et al. MOLECULAR CANCER THERAPEUTICS
- Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
- (2015) Jianhui Chang et al. NATURE MEDICINE
- Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy
- (2015) Joel D. Leverson et al. Science Translational Medicine
- Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
- (2015) J D Leverson et al. Cell Death & Disease
- Prognostic microRNAs modulate the RHO adhesion pathway: A potential therapeutic target in undifferentiated pleomorphic sarcomas
- (2015) Philip Wong et al. Oncotarget
- Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial
- (2014) Joal D. Beane et al. ANNALS OF SURGICAL ONCOLOGY
- Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas
- (2014) P. Wong et al. JNCI-Journal of the National Cancer Institute
- A community computational challenge to predict the activity of pairs of compounds
- (2014) Mukesh Bansal et al. NATURE BIOTECHNOLOGY
- Spatial and volumetric changes of retroperitoneal sarcomas during pre-operative radiotherapy
- (2014) Philip Wong et al. RADIOTHERAPY AND ONCOLOGY
- ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
- (2013) C. J. Vandenberg et al. BLOOD
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Neoadjuvant treatment of soft tissue sarcoma
- (2013) Daniela Greto et al. Radiologia Medica
- Selective BCL-2 Inhibition by ABT-199 Causes On-Target Cell Death in Acute Myeloid Leukemia
- (2013) R. Pan et al. Cancer Discovery
- Dying cell clearance and its impact on the outcome of tumor radiotherapy
- (2012) Kirsten Lauber et al. Frontiers in Oncology
- Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors
- (2011) Leena Gandhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Replication Stress Induces Micronuclei Comprising of Aggregated DNA Double-Strand Breaks
- (2011) Bing Xu et al. PLoS One
- Radiographic and Histologic Response to Neoadjuvant Radiotherapy in Patients With Soft Tissue Sarcoma
- (2010) Robert J. Canter et al. ANNALS OF SURGICAL ONCOLOGY
- DNA-SCARS: distinct nuclear structures that sustain damage-induced senescence growth arrest and inflammatory cytokine secretion
- (2010) F. Rodier et al. JOURNAL OF CELL SCIENCE
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
- (2010) Wyndham H Wilson et al. LANCET ONCOLOGY
- Radiological and pathological response following pre-operative radiotherapy for soft-tissue sarcoma
- (2010) David Roberge et al. RADIOTHERAPY AND ONCOLOGY
- Radiation-induced cell death mechanisms
- (2010) David Eriksson et al. TUMOR BIOLOGY
- Complete Soft Tissue Sarcoma Resection is a Viable Treatment Option for Select Elderly Patients
- (2009) G. Lahat et al. ANNALS OF SURGICAL ONCOLOGY
- Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
- (2009) Francis Rodier et al. NATURE CELL BIOLOGY
- A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
- (2009) Eric Campeau et al. PLoS One
- Accelerated senescence: An emerging role in tumor cell response to chemotherapy and radiation
- (2008) David A. Gewirtz et al. BIOCHEMICAL PHARMACOLOGY
- ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
- (2008) C. Tse et al. CANCER RESEARCH
- Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
- (2008) Thomas Kuilman et al. CELL
- Chemokine Signaling via the CXCR2 Receptor Reinforces Senescence
- (2008) Juan C. Acosta et al. CELL
- Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
- (2008) Jean-Philippe Coppé et al. PLOS BIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now